Sanofi makes it official–Brandicourt is its man

Eric Palmer Sanofi confirmed the rumors today, naming Paris-trained Olivier Brandicourt its new CEO. Brandicourt, who the French drugmaker stole away from the top pharma spot at Bayer ...

Roche and Exelixis roll toward FDA approval with a melanoma cocktail

Damian Garde Roche and Exelixis are one step closer to FDA approval for their skin cancer-treating combination treatment, as the agency has accepted their application and promised a ...

Who’s the new king of the drug launch hill? Hint: It’s all in the Gilead family

Tracy Staton Move over, Sovaldi–there's a new launch king in town. And luckily for Gilead, it's another of its own. Harvoni has officially unseated its hep C ...

Shire touts R&D benefits in defense of tax model

Nick Paul Taylor Shire CEO Flemming Ornskov has come out fighting against vocal critics of the company's tax model. As Ornskov sees it, Shire's tax structure is fully legal, ...

Novartis makes concerted push into Israeli biotech startup scene

Nick Paul Taylor Over the past year, Novartis has struck a pair of deals in Israel, snagging an option to buy Gamida Cell and a stake in BioLineRx. FierceBiotech News

Pharma wanted pricey orphan meds, and now it’s got ’em in record numbers

Carly Helfand New drug approvals were up last year, and orphan drug approvals were no exception. But by just how much did they climb? The FDA Law Blog has done some digging ...

Can Actavis deliver a promised $6B boost from this pipeline?

John Carroll FierceBiotech News

Say what? CVS Health execs figure PCSK9 meds to cost up to $150B

Tracy Staton CVS Health is raising eyebrows with a new estimate: A coming class of pricey cholesterol meds could cost the U.S. as much as $ 150 billion per year. FiercePharma ...

Activists want Ariad’s CEO out the door, report says

Damian Garde A year after taking a seat on Ariad Pharmaceuticals' board, activist investor Alex Denner is looking to oust CEO Harvey Berger, CNBC reports. FierceBiotech News

Bayer rolls up its sleeves for major reorg after plastics unit departs

Tracy Staton After Bayer hives off its plastics business, it's going to remake the rest. The German conglomerate will merge its HealthCare and CropScience divisions into one life-science-focused ...

Hedge funder’s first assault on iffy drug patents? Acorda’s MS med Ampyra

Tracy Staton Last month, Texas hedge fund manager Kyle Bass said he had pharma and its "questionable" patents in his sights. Now, he's made his first move–and he's ...

AstraZeneca struggles to spin out anti-infectives division, coming down to the wire

John Carroll The moment of truth is arriving for AstraZeneca's anti-infectives unit. For more than a year now, the pharma giant has been quietly shopping a deal, seeking an investor ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS